ABBOTT LABORATORIES acquired Exact Sciences Corporation for approximately $21 billion equity value (about $23 billion including net debt), a transaction completed in March 2026, structured as all cash.
Exact Sciences Corporation operates in Diagnostics — cancer screening & precision oncology, is based in Madison, Wisconsin, USA. Exact Sciences is a leader in large and fast-growing cancer screening and precision oncology diagnostics, best known for the Cologuard colorectal cancer screening test and the Oncotype DX cancer recurrence assays.
Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segments and advances Abbott's presence in oncology, one of the largest areas of unmet medical need.
Leadership position in cancer screening with the Cologuard franchise and a precision-oncology portfolio in a large, fast-growing diagnostics segment. Integrated into Abbott's Diagnostics business
Abbott has repeatedly taken on the world's most challenging health issues and made a meaningful impact on the lives of people in areas such as diabetes, cardiovascular disease and infectious disease. With Exact Sciences, we will do the same in cancer.Robert B. Ford, Chairman and CEO, Abbott
With the legacy and deep expertise of the Exact Sciences team, we're ready to transform cancer care.Abbott management, Exact Sciences completion release
Advisory firms were not disclosed for this transaction.